PRALUENT (alirocumab) injection is used for the treatment of patients with acute lymphoblastic leukemia (ALL)

PRALUENT is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).

PRALUENT (alirocumab) injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of PRALUENT (alirocumab) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the PRALUENT (alirocumab) injection medicine cost price in India.

The order for PRALUENT (alirocumab) injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Alirocumab (trade name Praluent)[1] is a biopharmaceutical drug approved by the FDA on July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval.

PRALUENTTM (alirocumab) injection, for subcutaneous use Initial U.S. Approval: 2015

Generic Name: Alirocumab

Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled pen
• Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled syringe

Praluent (alirocumab)

PRALUENT (alirocumab) injection is available.

Get In Touch

PRALUENT (alirocumab) injection suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand PRALUENT (alirocumab) injection on prescription and Import License in Patient's Name only.

For overseas patients, PRALUENT (alirocumab) injection can be made available in Send your enquiry to find PRALUENT (alirocumab) injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for PRALUENT (alirocumab) injection.

For PRALUENT (alirocumab) injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization For More Details

FDA Expands Indication for PCSK9 Alirocumab (Praluent) For More Details

Channel Partner In India

NEW DELHI OFFICE

  • Address:60/4, T&T House. Yusuf Sarai, New Delhi:110016
  • Phone +91-11-26532129
  • Email: IPN, New Delhi

BANGALORE OFFICE

  • Address: #308, Raheja Chambers, 12, Museum Road, Bangalore 560 001
  • Email: IPN, Bangalore

KOLKATA OFFICE

  • Address: 1/A R.G Kar Road, Shayambazar, Kolkata 700004
  • Email: IPN, Kolkata

LUCKNOW OFFICE

  • Address: 203-A, 2nd Floor, Tower -11, Felix Square, IBB-2, Sushant Golf city, Lucknow 226030
  • Email: IPN, Lucknow